Archive for the ‘Death by Stem Cells’ Category

A meeting of hearts if not minds

Thursday, February 2nd, 2012

Christina Blouvan-Cervantes had been battling aggressive leukemia when her blood count plummeted and she landed in the emergency room in Fresno. Her doctors told her a blood transfusion was her only hope. But her faith wouldn't allow her to receive one.

So she turned to one of the only doctors who could possibly keep her alive: a committed atheist who views her belief system as wholly irrational.

Dr. Michael Lill, head of the blood and marrow transplant program at Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute, is a last recourse for Jehovah's Witnesses with advanced leukemia.

PHOTOS: Doctor treats Jehovah's Witnesses

They arrive at Lill's door out of desperation and a desire to live. Many specialists decline to treat them because of their biblically centered refusal to accept blood transfusions, a mainstay of conventional care for the cancer.

Lill thinks their refusal is risky and illogical but nevertheless has devised a way to treat them that accommodates their religious convictions.

Despite his belief that God doesn't exist, he has become a hero to many devout believers.

“We don't care if he believes in God or not,” said David Goldfarb, chairman of the Los Angeles-area Hospital Liaison Committee for the Jehovah's Witnesses. “What we really believe in is, 'Are you a skilled and great doctor … and can you respect our belief system?'”

Lill, a 52-year-old Australian native, said ideological differences between doctor and patient are beside the point.

“Just because someone makes a decision which I would view as the wrong decision … doesn't mean at that point in time I say, 'No, I am not going to look after you anymore,' ” he said. “I try and treat people's religious beliefs with respect.”

::

Leukemia, a disease of the blood and bone marrow, produces cancerous blood cells. Treatment involves chemotherapy to destroy the cancerous cells, sometimes followed by transplants of stem cells that develop into healthy blood cells.

Blood transfusions are usually required, because both the cancer and the treatment suppresses the body's production of blood cells. Without transfusions, the risk of death from anemia or bleeding is significantly higher.

Jehovah's Witnesses draw their beliefs about blood from a literal interpretation of the Bible, which repeatedly warns against its consumption. Among the passages often cited by adherents: “You must not eat the blood; pour it out on the ground like water.”

It is a violation of God's command for a Jehovah's Witness to accept whole blood, red or white blood cells, platelets or plasma, Goldfarb said. It is left to patients to decide individually whether they are comfortable accepting stem cells.

Lill, who received his medical training in Australia, came to the United States in 1989 to work in the bone marrow transplant program at UCLA Medical Center. He accepted a position at Cedars-Sinai in 1997. He and his wife, a stem cell researcher, have two children.

He stumbled into the niche of treating Jehovah's Witnesses with leukemia after getting his first referral about 15 years ago. He saw both a professional challenge and an unmet need. Since then, about 50 Witnesses from around the world have come to his team for help, including 35 who have received stem cell transplants.

“People have the right to make their own decisions,” he said. Before treating the patients, Lill has a candid discussion about religion and medicine, freely using words like “death” and “dying.”

About four years ago, Lill himself was treated for cancer of the appendix. The experience, he said, helped him better understand his patients' fears.

Read more here:
A meeting of hearts if not minds

Don't Bet Against This Biotech IPO

Wednesday, February 1st, 2012

Verastem has good management.

View post:
Don't Bet Against This Biotech IPO

Juventas Therapeutics Reports One Year Data From Phase I Heart Failure Clinical Trial

Tuesday, January 31st, 2012

To: HEALTH, MEDICAL AND NATIONAL EDITORS

CLEVELAND, Jan. 30, 2012 /PRNewswire-USNewswire/ — Juventas Therapeutics is a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease. The Company's lead product, JVS-100, encodes Stromal cell-Derived Factor 1 (SDF-1) which has been shown to repair damaged tissue through recruitment of circulating stem cells to the site of injury, prevention of ongoing cell death and restoration of blood flow. Juventas recently presented the 12-month results from its Phase I heart failure trial at the 7th International Conference on Cell Therapy for Cardiovascular Disease.

(Logo: http://photos.prnewswire.com/prnh/20120130/DC43104LOGO)

The 17-person, open-label, dose-escalation study targeted New York Heart Association (NYHA) class III heart failure patients, who represent approximately a quarter of the 6 million heart failure patients in the United States and account for half of all heart failure hospital admissions. The clinical trial met its primary safety endpoint with no serious adverse events deemed drug related. Fifteen of the 17 patients survived to a year. Importantly, patients receiving target therapeutic doses demonstrated clinically significant improvements at 12 months in 6 minute walk distance (6MWD) and the Minnesota Living with Heart Failure Questionnaire (MLHFQ). Nearly half of the patients improved a full NYHA class, with multiple patients improving 2 full classes.

“The patient population we treated in this trial have a true unmet clinical need and tend to have rapidly deteriorating quality of life,” states Marc Penn, M.D., Ph.D, Founder and Chief Medical Officer for Juventas and Director of Cardiovascular Research at the Summa Cardiovascular Institute at Summa Health System. “To see clinical symptomatic benefits of this magnitude maintained from 4 to 12 months after JVS-100 treatment suggests we are inducing fundamental changes in the heart of treated patients. We believe this is consistent with our understanding of the mechanisms associated with JVS-100 and warrants further investigation.”

Based on these results, the company is preparing to enroll a placebo-controlled, randomized, double blinded Phase II heart failure clinical trial in the United States to further define the efficacy of JVS-100. Also, Juventas has received FDA clearance to enroll a Phase IIa trial evaluating safety and efficacy of JVS-100 in patients with critical limb ischemia. The CLI trial is enrolling patients in the United States and India. In addition to safety, the trial will assess time to amputation and other efficacy endpoints and will begin enrollment in the first quarter of 2012.

“We are thrilled by our Phase I data and excited to be transitioning into multiple mid-stage clinical trials,” states Rahul Aras, Ph.D., President and CEO for Juventas. “We are excited about the platform potential for JVS-100 in a broad range of clinical indications.”

About Juventas Therapeutics

Juventas Therapeutics, headquartered in Cleveland, OH, is a privately-held clinical-stage biotechnology company developing a pipeline of regenerative therapies to treat life-threatening diseases. Founded in 2007 with an exclusive license from the Cleveland Clinic, Juventas has transitioned its therapeutic platform from concept to initiation of mid-stage clinical trials. Investors include New Science Ventures, Takeda Ventures, Triathlon Medical Venture Partners, Early Stage Partners, Fletcher Spaght Ventures, Reservoir Venture Partners, North Coast Angel Fund, X Gen Ltd., JumpStart Inc., and Blue Chip Venture Co. The company has received non-dilutive grant support through the Ohio Third Frontier funded Cleveland Clinic Ohio BioValidation Fund, Global Cardiovascular Innovation Center and Center for Stem Cell & Regenerative Medicine.

About JVS-100

The company's lead product, JVS-100 encodes Stromal-cell Derived Factor 1 (SDF-1). SDF-1 promotes tissue repair through recruitment of endogenous stem cells to the damaged organ, promotion of new blood vessel formation and prevention of ongoing cell death. The SDF-1 repair pathway is well-conserved in a broad range of end organ systems, including the heart, vasculature, dermis, kidney, and eye. JVS-100 is currently being clinically evaluated for treatment of heart failure and late stage peripheral vascular disease and has been shown to protect and repair tissue following organ-damage in a broad range of pre-clinical disease models.

SOURCE Juventas Therapeutics

-0-

See more here:
Juventas Therapeutics Reports One Year Data From Phase I Heart Failure Clinical Trial

Grape seed extract shows cancer promise: Mouse study

Tuesday, January 31st, 2012

The study – published in Carcinogenesis – shows that grape seed extract (GSE) kills head and neck squamous cell carcinoma cells (HNSCC), while leaving healthy cells unharmed, in both in vitro and in vivo models.

View post:
Grape seed extract shows cancer promise: Mouse study

UCD stem cell research battles Huntington's disease

Sunday, January 29th, 2012

A team of researchers at UC Davis has pioneered a technique to
use stem cells to smother the genetic problem that causes
Huntington's disease.

The findings, due in the journal Molecular and Cellular
Neuroscience, could pave the way for a treatment that stops the
disease's devastating progression.

Huntington's is an inherited disease in which the body produces
a mutant version of a protein, huntingtin, that destroys nerve
cells in the brain.

It causes uncontrolled movements and difficulty walking, plus
dementia that grows progressively worse until the disease
ultimately results in death. It strikes about one in every
10,000 people in this country, according to the Huntington's
Disease Society of America.

There is no known cure. Treatment aims to slow down the
worsening of symptoms and keep the patient comfortable.

Researchers at the UC Davis Institute for Regenerative Cures,
led by Jan A. Nolta, attacked abnormal huntingtin with a
technique called RNA interference.

This is how it works: RNA is a molecule similar to DNA that
occurs naturally in the body and which cells use to produce
proteins.

If a strand of RNA is producing a bad protein, like the mutant
huntingtin, researchers can create another strand that's
essentially an inverted version of the bad one. Inject that new
molecule into a cell, and it locks onto the bad RNA like an
opposite puzzle piece, blocking it from making any protein.

For the first time, Nolta and colleagues were able to generate
huntingtin-blocking RNA in stem cells and inject them straight
into nerve cells – a treatment that significantly reduced the
amount of the mutant protein produced.

The scientists used stem cells derived from the bone marrow of
healthy human donors.

The California Institute for Regenerative Medicine and Team KJ
funded the research.

Nolta said the findings could lead to treatments for genetic
disorders such as ALS (Lou Gehrig's disease) and Parkinson's,
as well.

Now, she said, “Our challenge with RNA interference technology
is to figure out how to deliver it into the human brain in a
sustained, safe and effective manner. We're exploring how to
use human stem cells to create RNAi production factories within
the brain.”

Nolta's lab recently received funding from the California
Institute for Regenerative Medicine to develop an RNAi delivery
system for Huntington's disease.

©
Copyright The Sacramento Bee. All rights reserved.

Call The Bee's Grace Rubenstein, (916) 321-1270.

• Read more
articles by Grace Rubenstein

What You Should Know About Comments on Sacbee.com

Sacbee.com is happy to provide a forum for reader interaction,
discussion, feedback and reaction to our stories. However, we
reserve the right to delete inappropriate comments or ban users
who can't play nice. (See our full terms of
service here.)

Here are some rules of the road:

• Keep your comments civil. Don't insult one another or the
subjects of our articles. If you think a comment violates our
guidelines click the “Report Abuse” link to notify the
moderators. Responding to the comment will only encourage bad
behavior.

• Don't use profanities, vulgarities or hate speech. This is a
general interest news site. Sometimes, there are children
present. Don't say anything in a way you wouldn't want your own
child to hear.

• Do not attack other users; focus your comments on issues, not
individuals.

• Stay on topic. Only post comments relevant to the article at
hand.

• Do not copy and paste outside material into the comment box.

• Don't repeat the same comment over and over. We heard you the
first time.

• Do not use the commenting system for advertising. That's spam
and it isn't allowed.

• Don't use all capital letters. That's akin to yelling and not
appreciated by the audience.

• Don't flag other users' comments just because you don't agree
with their point of view. Please only flag comments that
violate these guidelines.

You should also know that The Sacramento Bee does not screen
comments before they are posted. You are more likely to see
inappropriate comments before our staff does, so we ask that
you click the “Report Abuse” link to submit those comments for
moderator review. You also may notify us via email at feedback@sacbee.com. Note the
headline on which the comment is made and tell us the profile
name of the user who made the comment. Remember, comment
moderation is subjective. You may find some material
objectionable that we won't and vice versa.

If you submit a comment, the user name of your account will
appear along with it. Users cannot remove their own comments
once they have submitted them.

View original post here:
UCD stem cell research battles Huntington's disease

Collaborative research sheds light on new cancer stem cell therapies

Sunday, January 29th, 2012

New anti-cancer research has led to the development of a novel class of chemical inhibitors that specifically target cancer cells with pluripotency.

Read more:
Collaborative research sheds light on new cancer stem cell therapies

Avastin's Failure in Breast Cancer: New Study May Explain Why It Happened

Saturday, January 28th, 2012

A new study may explain why the cancer drug Avastin hasn't worked in the treatment of breast cancer patients. Although the drug stops tumor growth for a short time, it often leads to more invasive tumors in the long run.

Go here to read the rest:
Avastin's Failure in Breast Cancer: New Study May Explain Why It Happened

Sepultura – Dead Embryonic Cell (lyrics) – Video

Friday, January 27th, 2012


10-02-2011 10:01 Lyrics: easylyrics.org Thanks for checking out our videos and site!

Read more:
Sepultura – Dead Embryonic Cell (lyrics) – Video

Alzheimer's brain cells grown from patients' skin cells could model disease

Thursday, January 26th, 2012

Brain cells from Alzheimer's patients have been grown in a highly purified form by San Diego and international scientists, producing models of the increasingly common neurodegenerative disease suitable for testing drugs.

The rest is here:
Alzheimer's brain cells grown from patients' skin cells could model disease

Ontario's first cardiac stem cell transplant performed last week

Thursday, January 26th, 2012

The first patient to receive this type of stem cell therapy, James Culross, a 67-year-old man from Etobicoke, will be discharged this week after 2.83 million stem cells [1] were injected into seven sites where his heart had been damaged by a heart attack [2] in November 2011.

Go here to read the rest:
Ontario's first cardiac stem cell transplant performed last week

Ontario's First Cardiac Stem Cell Transplant Performed Last Week at the Peter Munk Cardiac Centre

Thursday, January 26th, 2012

Heart failure is a leading cause of death in Canada. As part of the ongoing IMPACT-CABG clinical trial to treat advanced heart failure, physicians at the Peter Munk Cardiac Centre performed the first cardiac stem cell transplant in Ontario last week using stem cells derived from the patient's own bone marrow, isolated completely within the operating room, and implanted into the heart at the time …

Continued here:
Ontario's First Cardiac Stem Cell Transplant Performed Last Week at the Peter Munk Cardiac Centre

:: 26, Jan 2012 :: A*STAR SCHOLAR MEMBER OF CAMBRIGE TEAM FIRST TO GROW SMOOTH MUSCLE CELLS FROM PATIENT SKIN CELLS

Thursday, January 26th, 2012

A*STAR scholar Ms Christine Cheung was first author of a Nature Biotechnology paper published this month.

See the article here:
:: 26, Jan 2012 :: A*STAR SCHOLAR MEMBER OF CAMBRIGE TEAM FIRST TO GROW SMOOTH MUSCLE CELLS FROM PATIENT SKIN CELLS

Alzheimer's neurons from pluripotent stem cells: First-ever feat provides new method to understand cause of disease …

Wednesday, January 25th, 2012

Scientists have, for the first time, created stem cell-derived, in vitro models of sporadic and hereditary Alzheimer’s disease (AD), using induced pluripotent stem cells from patients with the much-dreaded neurodegenerative disorder.

Link:
Alzheimer's neurons from pluripotent stem cells: First-ever feat provides new method to understand cause of disease …

Alzheimer’s neurons induced from stem cells

Wednesday, January 25th, 2012

SAN DIEGO — Led by researchers at the University of California, San Diego School of Medicine, scientists have for the first time created stem cell-derived, in vitro models of sporadic and hereditary Alzheimer's disease, using induced pluripotent stem cells from patients with the much-dreaded neurodegenerative disorder.

Read the rest here:
Alzheimer’s neurons induced from stem cells

Alzheimers Neurons Created from Pluripotent Stem Cells

Wednesday, January 25th, 2012

Led by researchers at the University of California, San Diego School of Medicine, scientists have, for the first time, created stem cell-derived, in vitro models of sporadic and hereditary Alzheimer's disease (AD), using induced pluripotent stem cells from patients with the much-dreaded neurodegenerative disorder.

Visit link:
Alzheimers Neurons Created from Pluripotent Stem Cells

Danville veterinarian treating horses with stem cells

Wednesday, January 25th, 2012

A Danville veterinarian is delivering cutting-edge therapy to horses that may end up running at some of the most famous racetracks in the world. He said it is also helping man’s best friend.

More here:
Danville veterinarian treating horses with stem cells

Vision improves modestly in patients after human embryonic stem cells transplants

Tuesday, January 24th, 2012

The preliminary findings, published online [1] Jan.

Read this article:
Vision improves modestly in patients after human embryonic stem cells transplants

Adult stem cells could improve angioplasy outcome; Study to explore usage

Monday, January 23rd, 2012

A researcher is studying what role adult stem cells might play in repairing damaged coronary arteries, following angioplasty/stenting.

Read more:
Adult stem cells could improve angioplasy outcome; Study to explore usage

Adult Stem Cells Could Improve Angioplasy Outcome

Monday, January 23rd, 2012

A Creighton University School of Medicine researcher has received a $3.3 million grant to study what role adult stem cells might play in repairing damaged coronary arteries, following angioplasty/stenting.

More:
Adult Stem Cells Could Improve Angioplasy Outcome

team death in Dome and Seatown – Video

Monday, January 23rd, 2012


26-12-2011 19:33 i got lazy of waiting so i combined it

Read more from the original source:
team death in Dome and Seatown – Video





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research